Prostate Adenocarcinoma: Clinical Trials

17 trials for Prostate Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 5 active not recruiting, 2 recruiting, 1 terminated. 17 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 317Completed 9, Active not recruiting 5, Recruiting 2, Terminated 1
Phase 22Completed 2

Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedCurium US LLC2352024-04-012026-02-18
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma
Phase 3Active not recruitingCurium US LLC4392024-04-012026-10-27
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Biospecimen Collection, Bone Scan, Computed Tomography - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3RecruitingNRG Oncology15002023-12-142026-10-23
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma
Phase 3Active not recruitingNRG Oncology20502021-12-062026-08-17
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Ga-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedUniversity of Colorado, Denver392021-09-292023-11-13
Ga-68-PSMA-11 in Men With Prostate Cancer
Ga-68-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma
Phase 3TerminatedTimothy Hoffman382021-07-272023-02-24
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3Active not recruitingNRG Oncology27532021-01-212026-08-17
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Cabozantinib, Atezolizumab, Abiraterone Acetate - Metastatic Prostate Cancer, Prostate Adenocarcinoma
Phase 3Active not recruitingExelixis5752020-10-192025-12-18
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 3RecruitingECOG-ACRIN Cancer Research Group8042020-10-082026-11-13
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Phase 3Active not recruitingNRG Oncology5862020-04-162026-11-18
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
18F-DCFPyL, PET/CT Imaging - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedProgenics Pharmaceuticals, Inc.2082018-11-272021-06-14
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
C-11 choline PET tracer, Gadobutrol, PET/MR scanner - Prostate Adenocarcinoma
Phase 3CompletedMayo Clinic192017-11-012021-02-08
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7
Phase 3CompletedNRG Oncology2962017-07-282026-07-09
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET) - Prostate Adenocarcinoma, PSA Failure
Phase 2 / Phase 3CompletedAndrei Iagaru612017-05-202022-01-13
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Phase 3CompletedJonsson Comprehensive Cancer Center11382016-09-152021-07-02
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography - Prostate Adenocarcinoma
Phase 2 / Phase 3CompletedAndrei Iagaru1222015-11-162023-04-10
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
Short term androgen deprivation, Long term androgen deprivation - Prostate Adenocarcinoma
Phase 3CompletedFundación de Investigación Biomédica - Hospital Universitario de La Princesa3622005-11-012020-11-20

Narrower conditions

Prostatic Neoplasms (13)  ·  Disease (1)

Broader conditions

Genital Diseases (13)  ·  Genital Diseases, Male (13)  ·  Genital Neoplasms, Male (13)  ·  Male Urogenital Diseases (13)  ·  Neoplasms (13)  ·  Neoplasms by Site (13)  ·  Prostatic Diseases (13)  ·  Urogenital Diseases (13)  ·  Urogenital Neoplasms (13)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Magnetic Resonance Spectroscopy (7)  ·  Radiation (6)  ·  Radiotherapy (4)  ·  Goserelin (3)  ·  Leuprolide (3)  ·  Specimen Handling (3)  ·  Triptorelin Pamoate (3)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (3)  ·  apalutamide (3)  ·  gallium 68 PSMA-11 (3)  ·  relugolix (3)  ·  Buserelin (2)  ·  Congresses as Topic (2)  ·  Flutamide (2)  ·  Radiosurgery (2)

Sponsors

NRG Oncology (5)  ·  Andrei Iagaru (2)  ·  Curium US LLC (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Exelixis (1)  ·  Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Mayo Clinic (1)  ·  Progenics Pharmaceuticals, Inc. (1)  ·  Timothy Hoffman (1)  ·  University of Colorado, Denver (1)

Countries

United States (16)  ·  Canada (7)  ·  Singapore (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  Czechia (1)  ·  France (1)  ·  Georgia (1)  ·  Germany (1)

Top investigators

Almudena Zapatero, MD PhD, IP (1)  ·  Andrei Iagaru (1)  ·  Andrei Iagaru, MD (1)  ·  Bennett Chin (1)  ·  Jessica D Jensen (1)  ·  Johannes Czernin, MD (1)  ·  Karen E Hoffman (1)  ·  Mark K Buyyounouski (1)  ·  Ming Yang (1)  ·  Neha Vapiwala (1)  ·  Neil B Desai (1)  ·  Paul L Nguyen (1)  ·  Ronald C Chen (1)  ·  Timothy J Hoffman, PhD (1)

Results publications

PMID 38421243, PMID 16170164, PMID 25702876, PMID 27598804, PMID 29242398, PMID 29242404, PMID 30920593, PMID 31375469, PMID 31478089, PMID 32808077, PMID 33674398, PMID 34406051, PMID 35034502, PMID 35427469, PMID 37555901, PMID 38423030, PMID 38483412, PMID 40523369, PMID 41698328, PMID 41806372

NIH funding

U10CA180868 (5), U10CA180820 (1)